Applied Therapeutics IncNASDAQ:APLT
- LAST PRICE5.0500
- TODAY'S CHANGE (%)-0.2100 (-3.9924%)
- Bid / Lots4.7500/ 1
- Ask / Lots5.2500/ 8
- Open / Previous Close5.2300 / 5.2600
- Day Range
- 52 Week Range
- Volume672,435
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APLT |
|---|---|---|
| 09:32 ET | 12789 | 5.185 |
| 09:34 ET | 2200 | 5.28 |
| 09:36 ET | 384 | 5.26 |
| 09:38 ET | 2758 | 5.17 |
| 09:39 ET | 700 | 5.15 |
| 09:41 ET | 30045 | 5.1 |
| 09:43 ET | 3163 | 5.045 |
| 09:45 ET | 1885 | 5.085 |
| 09:48 ET | 1000 | 5.085 |
| 09:50 ET | 2469 | 5.085 |
| 09:52 ET | 1600 | 5.09 |
| 09:54 ET | 800 | 5.12 |
| 09:56 ET | 1600 | 5.14 |
| 09:57 ET | 5582 | 5.135 |
| 09:59 ET | 831 | 5.14 |
| 10:01 ET | 1000 | 5.15 |
| 10:03 ET | 100 | 5.18 |
| 10:06 ET | 548 | 5.1789 |
| 10:08 ET | 363 | 5.18 |
| 10:10 ET | 802 | 5.1718 |
| 10:12 ET | 400 | 5.18 |
| 10:14 ET | 3362 | 5.13 |
| 10:15 ET | 1400 | 5.155 |
| 10:21 ET | 500 | 5.16 |
| 10:24 ET | 4509 | 5.205 |
| 10:26 ET | 1707 | 5.22 |
| 10:28 ET | 200 | 5.22 |
| 10:30 ET | 3462 | 5.23 |
| 10:32 ET | 1795 | 5.229 |
| 10:33 ET | 1300 | 5.23 |
| 10:35 ET | 9654 | 5.17 |
| 10:37 ET | 300 | 5.16 |
| 10:39 ET | 1782 | 5.18 |
| 10:42 ET | 3027 | 5.18 |
| 10:44 ET | 899 | 5.1 |
| 10:46 ET | 1210 | 5.08 |
| 10:48 ET | 1350 | 5.08 |
| 10:51 ET | 700 | 5.08 |
| 10:53 ET | 1450 | 5.105 |
| 10:55 ET | 1691 | 5.08 |
| 10:57 ET | 423 | 5.06 |
| 11:00 ET | 1000 | 5.07 |
| 11:02 ET | 500 | 5.08 |
| 11:04 ET | 100 | 5.08 |
| 11:06 ET | 17433 | 5.065 |
| 11:08 ET | 700 | 5.065 |
| 11:09 ET | 1867 | 5.06 |
| 11:11 ET | 4000 | 5.085 |
| 11:13 ET | 7680 | 5.105 |
| 11:15 ET | 1387 | 5.11 |
| 11:18 ET | 1251 | 5.1 |
| 11:22 ET | 200 | 5.07 |
| 11:24 ET | 55268 | 5.01 |
| 11:26 ET | 1100 | 5.015 |
| 11:27 ET | 1200 | 5.04 |
| 11:29 ET | 18099 | 5.01 |
| 11:31 ET | 22943 | 4.95 |
| 11:33 ET | 600 | 4.95 |
| 11:36 ET | 6068 | 4.95 |
| 11:38 ET | 4839 | 5 |
| 11:40 ET | 1805 | 5.02 |
| 11:42 ET | 100 | 5.01 |
| 11:47 ET | 2318 | 5 |
| 11:49 ET | 7141 | 5 |
| 11:51 ET | 200 | 5 |
| 11:54 ET | 5257 | 5 |
| 11:56 ET | 619 | 5 |
| 11:58 ET | 1200 | 5.015 |
| 12:00 ET | 497 | 5.02 |
| 12:05 ET | 900 | 5.035 |
| 12:07 ET | 2381 | 5.039 |
| 12:09 ET | 2649 | 5.02 |
| 12:12 ET | 575 | 5.05 |
| 12:14 ET | 1722 | 5.04 |
| 12:16 ET | 900 | 5.04 |
| 12:21 ET | 200 | 5.04 |
| 12:23 ET | 139 | 5.0482 |
| 12:25 ET | 2153 | 5.02 |
| 12:27 ET | 903 | 5 |
| 12:30 ET | 358 | 5.01 |
| 12:32 ET | 100 | 5.01 |
| 12:34 ET | 2100 | 5.01 |
| 12:36 ET | 700 | 5.01 |
| 12:38 ET | 9312 | 5.05 |
| 12:39 ET | 4557 | 5.06 |
| 12:41 ET | 979 | 5.065 |
| 12:43 ET | 400 | 5.07 |
| 12:45 ET | 2189 | 5.075 |
| 12:48 ET | 4105 | 5.07 |
| 12:50 ET | 200 | 5.07 |
| 12:52 ET | 1119 | 5.05 |
| 12:54 ET | 374 | 5.04 |
| 12:56 ET | 100 | 5.035 |
| 12:57 ET | 2838 | 5.04 |
| 12:59 ET | 1400 | 5.055 |
| 01:03 ET | 3282 | 5.07 |
| 01:06 ET | 500 | 5.075 |
| 01:08 ET | 400 | 5.075 |
| 01:10 ET | 9132 | 5.1 |
| 01:12 ET | 6619 | 5.09 |
| 01:14 ET | 669 | 5.07 |
| 01:17 ET | 100 | 5.06 |
| 01:19 ET | 756 | 5.07 |
| 01:24 ET | 2066 | 5.06 |
| 01:26 ET | 6365 | 5.07 |
| 01:30 ET | 100 | 5.075 |
| 01:32 ET | 100 | 5.075 |
| 01:33 ET | 500 | 5.075 |
| 01:35 ET | 100 | 5.075 |
| 01:37 ET | 200 | 5.07 |
| 01:39 ET | 500 | 5.075 |
| 01:42 ET | 625 | 5.075 |
| 01:44 ET | 3446 | 5.065 |
| 01:46 ET | 100 | 5.0606 |
| 01:48 ET | 400 | 5.065 |
| 01:50 ET | 143 | 5.065 |
| 01:51 ET | 1902 | 5.04 |
| 01:53 ET | 2629 | 5.05 |
| 01:55 ET | 1881 | 5.04 |
| 01:57 ET | 3726 | 5.02 |
| 02:00 ET | 400 | 5.02 |
| 02:02 ET | 200 | 5.03 |
| 02:04 ET | 1528 | 5.015 |
| 02:06 ET | 1722 | 5.02 |
| 02:08 ET | 442 | 5.02 |
| 02:09 ET | 400 | 5.02 |
| 02:11 ET | 100 | 5.02 |
| 02:13 ET | 200 | 5.02 |
| 02:15 ET | 4643 | 5.01 |
| 02:18 ET | 200 | 5 |
| 02:20 ET | 2062 | 5.01 |
| 02:22 ET | 100 | 5 |
| 02:24 ET | 100 | 5 |
| 02:26 ET | 100 | 5.005 |
| 02:27 ET | 200 | 5.005 |
| 02:29 ET | 200 | 5 |
| 02:31 ET | 1000 | 5.01 |
| 02:33 ET | 9983 | 5 |
| 02:38 ET | 300 | 5.01 |
| 02:40 ET | 421 | 5.01 |
| 02:42 ET | 200 | 5.01 |
| 02:44 ET | 532 | 5.01 |
| 02:45 ET | 381 | 5.01 |
| 02:47 ET | 708 | 5.005 |
| 02:49 ET | 1000 | 5.005 |
| 02:51 ET | 1877 | 5.02 |
| 02:54 ET | 300 | 5.025 |
| 02:56 ET | 977 | 5.03 |
| 02:58 ET | 1807 | 5.045 |
| 03:00 ET | 3772 | 5.06 |
| 03:02 ET | 2032 | 5.08 |
| 03:03 ET | 2296 | 5.07 |
| 03:05 ET | 2990 | 5.07 |
| 03:07 ET | 100 | 5.07 |
| 03:12 ET | 6805 | 5.07 |
| 03:14 ET | 910 | 5.05 |
| 03:16 ET | 107 | 5.055 |
| 03:18 ET | 4702 | 5.05 |
| 03:20 ET | 100 | 5.06 |
| 03:21 ET | 1600 | 5.07 |
| 03:23 ET | 300 | 5.09 |
| 03:25 ET | 1869 | 5.09 |
| 03:27 ET | 400 | 5.095 |
| 03:30 ET | 517 | 5.095 |
| 03:32 ET | 1200 | 5.1 |
| 03:34 ET | 4143 | 5.09 |
| 03:36 ET | 100 | 5.1 |
| 03:38 ET | 2296 | 5.09 |
| 03:39 ET | 2408 | 5.07 |
| 03:41 ET | 839 | 5.075 |
| 03:43 ET | 500 | 5.07 |
| 03:45 ET | 4072 | 5.075 |
| 03:48 ET | 1200 | 5.08 |
| 03:50 ET | 2829 | 5.09 |
| 03:52 ET | 4414 | 5.1 |
| 03:54 ET | 1800 | 5.1 |
| 03:56 ET | 10151 | 5.05 |
| 03:57 ET | 11280 | 5.065 |
| 03:59 ET | 59606 | 5.05 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Applied Therapeutics Inc | 577.1M | -2.6x | --- |
Iteos Therapeutics Inc | 586.3M | -4.3x | --- |
Arbutus Biopharma Corp | 592.6M | -7.1x | --- |
Lexeo Therapeutics Inc | 572.6M | -6.4x | --- |
Annexon Inc | 581.6M | -3.8x | --- |
Savara Inc | 563.8M | -10.6x | --- |
Company Information
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Contact Information
- Headquarters
- 545 FIFTH AVENUE, SUITE 1400NEW YORK, NY, United States 10017
- Phone
- 212-220-9226
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Shoshana Shendelman
- Chief Financial Officer and Principal Financial Officer, Director
- Leslie Funtleyder
- Chief Operating Officer and Chief Business Officer
- Constantine Chinoporos
- Chief Accounting Officer
- Catherine Thorpe
- Chief Commercial Officer
- Dale Hooks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $577.1M |
|---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.00 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
